Takeda Pharmaceutical Company Limited

4502

JP3463000004

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:30:00 2025-07-07 EDT			5-day change	1st Jan Change
4,412.00 ^JPY	-0.63%		+1.05%	+5.52%

11:03am	US FDA approves KalVista's oral swelling disorder drug, shares rise	RE
06-30	Takeda Pharmaceutical Company Limited Announces U.S. FDA Approval of Gammard Liquid Immunoglobulin Therapy with Low Immunoglobulin A Content	CI

Takeda to Withdraw, Replace Shelf Registration to Support Incentive Plan

Published on 2025-06-03 at 08:26

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Takeda Pharmaceutical Company Limited

US FDA approves KalVista's oral swelling disorder drug, shares rise	11:03am	RE
Takeda Pharmaceutical Company Limited Announces U.S. FDA Approval of Gammard Liquid Immunoglobulin Therapy with Low Immunoglobulin A Content	06-30	CI
Takeda Pharmaceutical Receives FDA Approval for Ready-to-Use Liquid Immunoglobulin Therapy	06-30	MT
Takeda Pharmaceuticals Gets FDA Approval for Liquid Gammagard	06-30	DJ
S&P Rates Takeda Pharmaceutical US Unit's Notes BBB+	06-27	MT
Takeda Pharmaceutical Company Limited, 2025 Earnings Call, May 08, 2025	06-26
Takeda Pharmaceutical Company Limited Announces Change in Compensation Committee Members, Effective June 25, 2025	06-25	CI
Takeda Pharmaceutical Company Limited - Special Call	06-10
Keros Therapeutics Shareholder Seeks $475 Million Dividend; Threatens to Nominate New Directors at 2026 Annual Meeting	06-09	MT
Trump's tariffs and threatened trade actions	06-04	RE
Trump's tariffs and threatened trade actions	06-04	RE
European Commission Approves Adcetris®? (Brentuximab Vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage Iib/Iii/Iv Hodgkin Lymphoma in Combination with Ecadd	06-03	CI
Takeda Pharmaceutical Receives European Commission Approval for Adcetris Regimen to Treat Hodgkin Lymphoma	06-03	MT
Takeda to Withdraw, Replace Shelf Registration to Support Incentive Plan	06-03	MT
Takeda Pharmaceutical Says Co Will File Shelf Registration Statement In Japan	06-02	RE
Protagonist Therapeutics, Inc. and Takeda Announce Asco Plenary Presentation Highlighting Full 32-Week Results from Phase 3 Verify Study of Rusfertide	06-02	CI
Protagonist Therapeutics, Takeda's Potential Polycythemia Vera Drug Meets Primary Endpoint	06-02	MT
Takeda Presents Clinical Data of Polycythemia Vera Treatment at Oncology Conference	06-02	MT
Trump's tariffs and threatened trade actions	05-30	RE
Veeva Systems Shares Rise After Q1 Results Top Expectations	05-29	MT
Trump's tariffs and threatened trade actions	05-28	RE
Xoma Royalty Acquires Mezagitamab Royalty, Milestone Rights From BioInvent	05-27	MT
GLP-1 diabetes drugs like Ozempic may modestly reduce cancer risks	05-22	RE
Health Rounds: Older diabetes drugs appear to slow prostate cancer in small study	05-21	RE
Takeda Announces The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1	05-14	CI

Chart Takeda Pharmaceutical Company Limited

Duration

Period

Chart Takeda Pharmaceutical Company Limited

4502: Dynamic Chart

Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.

Employees

47,455

Sector

Pharmaceuticals

Calendar

07-29 - Q1 2025 Earnings Release

More about the company